Myotonic dystrophy type 1 drug development: A pipeline toward the market

Myotonic dystrophy type 1 (DM1) is a multisystemic neuromuscular genetic disease with an estimated prevalence of approximately at least half a million individuals based on its vast ethnic variation. Building upon a well-known physiopathology and several proof-of-concept therapeutic approaches, herei...

Descripción completa

Detalles Bibliográficos
Autores principales: Pascual-Gilabert, Marta, López-Castel, Arturo, Artero, Ruben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science Ltd. ;, Distributed by Virgin Mailing and Distribution 2021
Materias:
Post-Screen (Grey)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372527/
https://www.ncbi.nlm.nih.gov/pubmed/33798646
http://dx.doi.org/10.1016/j.drudis.2021.03.024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372527/
https://www.ncbi.nlm.nih.gov/pubmed/33798646
http://dx.doi.org/10.1016/j.drudis.2021.03.024

Ejemplares similares